INVITRO ACTIVITY OF RAMOPLANIN AGAINST VANCOMYCIN-RESISTANT GRAM-POSITIVE ORGANISMS

In vitro activity of ramoplanin, a cyclic lipoglycopeptide, against 92 vancomycin-resistant gram-positive organisms was evaluated. Ramoplani n demonstrated potent activity against many highly vancomycin-resistan t organisms including enterococci (MICs for 90% of strains tested of 0 .5 mug/ml) and against Lactobacillus spp., Leuconostoc spp., and Pedio coccus spp., all of which were inhibited at concentrations of less-tha n-or-equal-to 0.25 mug/ml. This drug or a derivative compound merits f urther investigation as a potential therapeutic agent for infections d ue to vancomycin-resistant enterococci.